Latest Oncology News

Tucatinib Plus Trastuzumab Induces Durable Tumor Response in HER2+ mCRC

Tucatinib Plus Trastuzumab Induces Durable Tumor Response in HER2+ mCRC

July 2nd 2022

Brittany Lovely

Patients with previously treated metastatic HER2-positive colorectal cancer experienced clinically meaningful and durable responses to treatment with tucatinib plus trastuzumab, according to data from the phase 2 MOUNTAINEER trial.

Mirvetuximab Soravtansine Displays Promising Efficacy in Platinum-Resistant Ovarian Cancer

Mirvetuximab Soravtansine Displays Promising Efficacy in Platinum-Resistant Ovarian Cancer

July 2nd 2022

Kyle Doherty

Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options.

ALRN-6924 Halts Development in P53-Mutant NSCLC, Advances in P53-Mutant Breast Cancer

ALRN-6924 Halts Development in P53-Mutant NSCLC, Advances in P53-Mutant Breast Cancer

July 1st 2022

Caroline Seymour

Drug manufacturer Aileron plans to stop further enrollment into a phase 1b trial (NCT04022876) after the chemoprotective agent ALRN-6924 missed its composite primary end point for patients with advanced p53-mutant non–small cell lung cancer.

KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC

KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC

July 1st 2022

Brittany Lovely

Efforts to unlock treatment modalities targeting KRAS mutations have ebbed and flowed for patients with non–small cell lung as investigators face resistance, intolerable toxicity profiles, and a lack of available binding pockets to guide treatment development.

FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL

FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL

July 1st 2022

Chris Ryan

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Latest Oncology Videos

All Oncology News

Darolutamide Crossover Leads to High PSA Response in Nonmetastatic CRPC

July 12th 2021

Gina Mauro

Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.

Tucatinib Detectable in CSF of HER2+ Metastatic Breast Cancer With Leptomeningeal Disease

July 12th 2021

Ryan Scott

Tucatinib and ONT-993 were found to be detectable in the cerebrospinal fluid of all patients with leptomeningeal metastases from HER2-positive metastatic breast cancer who received treatment with tucatinib plus trastuzumab and capecitabine.

Apalutamide Plus ADT Improves Survival Regardless of Disease Volume in mCSPC

July 12th 2021

Brittany Lovely

Investigators demonstrated that the benefit of androgen deprivation therapy was extended with the addition of apalutamide for patients with metastatic castration-sensitive prostate cancer regardless of disease volume.

Neoadjuvant Apalutamide Does Not Interfere With Robotic Prostatectomy

July 12th 2021

Kyle Doherty

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Treatment Considerations in DLBCL

July 12th 2021

John P. Leonard, MD, Weill Cornell Medicine

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

Treating Newly Diagnosed Patients With DLBCL

July 12th 2021

John P. Leonard, MD, Weill Cornell Medicine

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

Recent FDA Approvals in Gastric and GEJ Cancers

July 12th 2021

Daniel Catenacci, MD, University of Chicago Medicine

Daniel Catenacci, MD, and Sam Klempner, MD, consider the overall impact of recently approved immunotherapy-based regimens for gastric and gastroesophageal junction cancers.

Historical Perspective on Treatment of Gastric and GEJ Cancers 

July 12th 2021

Daniel Catenacci, MD, University of Chicago Medicine

Experts in the management of gastric cancer provide a historical perspective on available treatment options.

CDK4/6 Inhibitors Show Hints of Activity in Early-Stage HR+/HER2- Breast Cancer

July 12th 2021

Jessica Hergert

Halle Moore, MD, discusses the data that support the use of CDK4/6 inhibitors plus endocrine therapy in HR-positive, HER2-negative breast cancer, how to select between available CDK4/6 inhibitors in the metastatic setting, and the current state of this treatment approach for patients with early-stage disease.

FDA Approves Subcutaneous Daratumumab Plus Pd for Multiple Myeloma at First or Subsequent Relapse

July 12th 2021

Kristi Rosa

The FDA has approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro) plus pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide and a proteasome inhibitor

Breast Cancer: Chaired by Martine Extermann, MD, PhD

July 12th 2021

Belapectin/Pembrolizumab Shows Early Activity, Tolerability in Metastatic Melanoma & Head and Neck Cancer

July 11th 2021

Kristi Rosa

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer.

Patients With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10th 2021

Kristi Rosa

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

Sequential Mitomycin/BCG Combo Shows Preliminary Safety in High-Risk NMIBC

July 10th 2021

Gina Mauro

Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 10th 2021

Evangelia Sereti, MSc, PhD

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

See All News